Kris is an Associate Professor at Duke University in the Department of Pharmacology and Cancer Biology, where he leads a team of researchers focused on understanding the links between cancer genomics, cell death regulation, and tumor evolution. To systematize the discovery process, Kris and his team have pioneered and adapted a range of new functional genomic tools with powerful applications in drug discovery. Kris is also a co-founder of Celldom, a company developing image-based single cell biology platforms, and Element Genomics, a company focused on understanding non-coding regulatory elements in the human genome using CRISPR/Cas9 based approaches (acquired by UCB Pharma in 2018). Kris received his PhD in Chemical Engineering from MIT and subsequently trained as an NIH postdoctoral fellow in cancer genomics in Dr. David Sabatini’s lab at the Whitehead and Broad Institutes of MIT and Harvard. For his contributions to cancer research, Kris has received various awards, including a Stewart Trust Fellowship, a V Scholar Award from the V Foundation for Cancer Research, and Breakthrough Awards from the U.S. Department of Defense.